How many insider declarations has KKR Genetic Disorder L.P. filed?

KKR Genetic Disorder L.P. has filed 3 public insider declarations with SEC (Form 4).

What is KKR Genetic Disorder L.P.'s role?

KKR Genetic Disorder L.P.'s reported role is not specified by the regulator across the filings.

Which companies does KKR Genetic Disorder L.P. report trades for?

KKR Genetic Disorder L.P. reports trades for BridgeBio Pharma, Inc..

What is KKR Genetic Disorder L.P.'s declared buy vs sell volume?

Across the available history, declared buys total 0 and disposals 505.8M€.

← Executives ★ Sign in to follow

KG

KKR Genetic Disorder L.P.

·SEC (Form 4)

BridgeBio Pharma, Inc.

累计流向

0

申报总数

0

公司

—

▲ 买入（0 笔）

€5亿

▼ 卖出（3 笔）

内部人交易记录

其他

已披露买入

0

已披露卖出

3

尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。

信号历史

Explore the complete record of transactions filed by KKR Genetic Disorder L.P.. Director active across 1 company, notably BridgeBio Pharma, Inc.. Aggregated, 3 filings have been published. Breakdown: 0 buy · 3 sells. Total volume traded: €505.8m. History available since 13 September 2024. The latest transaction was disclosed on 12 May 2025 (Cession). Regulator: SEC (Form 4). The full history is openly available.

Companies and markets linked to KKR Genetic Disorder L.P.

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

BridgeBio Pharma, Inc. (US)

申报3 总计

▼

KKR Genetic Disorder L.P.

高管2025年5月12日BridgeBio Pharma, Inc.

US$2亿24SEC ↗

6,000,000 股@ US$34.2036.6% 占其流量Common StockSEC:0001140361-25-019003:0

▼

KKR Genetic Disorder L.P.

高管2025年3月5日BridgeBio Pharma, Inc.

US$2亿18SEC ↗

6,000,000 股@ US$32.9636.8% 占其流量Common StockSEC:0001140361-25-007699:0

▼

KKR Genetic Disorder L.P.

高管2024年9月13日BridgeBio Pharma, Inc.

US$1亿5SEC ↗

5,800,000 股@ US$25.7526.7% 占其流量Common StockSEC:0001140361-24-041329:0

3 条申报中的 3 条

InsidersTradesSigma

← Executives ★ Sign in to follow

KG

KKR Genetic Disorder L.P.

·SEC (Form 4)

BridgeBio Pharma, Inc.

累计流向

0

申报总数

0

公司

—

▲ 买入（0 笔）

€5亿

▼ 卖出（3 笔）

内部人交易记录

其他

已披露买入

0

已披露卖出

3

尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。

信号历史

Explore the complete record of transactions filed by KKR Genetic Disorder L.P.. Director active across 1 company, notably BridgeBio Pharma, Inc.. Aggregated, 3 filings have been published. Breakdown: 0 buy · 3 sells. Total volume traded: €505.8m. History available since 13 September 2024. The latest transaction was disclosed on 12 May 2025 (Cession). Regulator: SEC (Form 4). The full history is openly available.